G protein-coupled receptor (GPCR) gene variants and human genetic disease

References

• Spiegel AM. Introduction to G-protein coupled signal transduction and human disease. In: Spiegel AM, editor. G proteins, receptors, and disease. Totowa (NJ): Humana Press; 1998:1–21.
   Google Scholar
• Hauser AS, Attwood MM, Rask-Andersen M, et al. Trends in GPCR drug discovery: new agents, targets and indications. Nat Rev Drug Discov. 2017;16(12):829–842. doi: 10.1038/nrd.2017.178.
   PubMed Web of Science ®Google Scholar
• Hauser AS, Chavali S, Masuho I, et al. Pharmacogenomics of GPCR drug targets. Cell. 2018;172(1–2):41–54.e19. doi: 10.1016/j.cell.2017.11.033.
   PubMed Web of Science ®Google Scholar
• Hauser AS. Personalized medicine through GPCR pharmacogenomics. In: Kenakin T, editor. Comprehensive pharmacology. Amsterdam (NL): Elsevier; 2021. p. 2022191–2022219.
   Google Scholar
• Hauser AS, Gloriam DE, Bräuner-Osborne H, et al. Novel approaches leading towards peptide GPCR de-orphanisation. Br J Pharmacol. 2019;177(5):961–968. doi: 10.1111/bph.14950.
   Web of Science ®Google Scholar
• Shrivastava A, Mathur K, Verma RK, et al. Molecular dynamics study of tropical calcific pancreatitis (TCP) associated calcium-sensing receptor single nucleotide variation. Front Mol Biosci. 2022;9:982831. doi: 10.3389/fmolb.2022.982831.
   PubMed Web of Science ®Google Scholar
• Tao Y-T. Inactivating mutations of G protein-coupled receptors and diseases: structure-function insights and therapeutic implications. Pharmacol Ther. 2006;111(3):949–973. doi: 10.1016/j.pharmthera.2006.02.008.
   PubMed Web of Science ®Google Scholar
• Tao Y-T, Conn PM. Chaperoning G protein-coupled receptors: from cell biology to therapeutics. Endocr Rev. 2014;35(4):602–647. doi: 10.1210/er.2013-1121.
   PubMed Web of Science ®Google Scholar
• Tao Y-X. Constitutive activation of G protein-coupled receptors and diseases: insights into mechanisms of activation and therapeutics. Pharmacol Ther. 2008;120(2):129–148. doi: 10.1016/j.pharmthera.2008.07.005.
   PubMed Web of Science ®Google Scholar
• Daiger SP, Sullivan LS, Bowne SJ. Genes and mutations causing retinitis pigmentosa. Clin Genet. 2013;84(2):132–141. doi: 10.1111/cge.12203.
   PubMed Web of Science ®Google Scholar
• Roushar FJ, McKee AG, Kuntz CP, et al. Molecular basis for variations in the sensitivity of pathogenic rhodopsin variants to 9-cis-retinal. J Biol Chem. 2022;298(8):102266. doi: 10.1016/j.jbc.2022.102266.
   PubMed Web of Science ®Google Scholar
• Dryja TP, McGee TL, Reichel E, et al. A point mutation of the rhodopsin gene in one form of retinitis pigmentosa. Nature. 1990;343(6256):364–366. doi: 10.1038/343364a0.
   PubMed Web of Science ®Google Scholar
• Sudharsan R, Beltran WA. Progress in gene therapy for rhodopsin autosomal dominant retinitis pigmentosa. Adv Exp Med Biol. 2019;1185:113–118. doi: 10.1007/978-3-030-27378-1_19.
   PubMed Web of Science ®Google Scholar
• Rim J, Oprian DD. Constitutive activation of opsin—interaction of mutants with rhodopsin kinase and arrestin. Biochemistry. 1995;34(37):11938–11945. doi: 10.1021/bi00037a035.
   PubMed Web of Science ®Google Scholar
• Bunge S, Wedemann H, David D, et al. Molecular analysis and genetic-mapping of the rhodopsin gene in families with autosomal dominant retinitis pigmentosa. Genomics. 1993;17(1):230–233. doi: 10.1006/geno.1993.1309.
   PubMed Web of Science ®Google Scholar
• Farrar GJ, Mcwilliam P, Bradley DG, et al. Autosomal dominant retinitis pigmentosa—linkage to rhodopsin and evidence for genetic-heterogeneity. Genomics. 1990;8(1):35–40. doi: 10.1016/0888-7543(90)90223-h.
   PubMed Web of Science ®Google Scholar
• Inglehearn CF, Lester DH, Bashir R, et al. Recombination between rhodopsin and locus D3S47 (C17) in rhodopsin retinitis pigmentosa families. Am J Hum Genet. 1992;50(3):590–597.
   PubMed Web of Science ®Google Scholar
• Neidhardt J, Barthelmes D, Farahmand F, et al. Different amino acid substitutions at the same position in rhodopsin lead to distinct phenotypes. Invest Ophthalmol Vis Sci. 2006;47(4):1630–1635. doi: 10.1167/iovs.05-1317.
   PubMed Web of Science ®Google Scholar
• Andres A, Kosoy A, Garriga P, et al. Mutations at position 125 in transmembrane helix III of rhodopsin affect the structure and signalling of the receptor. Eur J Biochem. 2001;268(22):5696–5704. doi: 10.1046/j.0014-2956.2001.02509.x.
   PubMedGoogle Scholar
• Jones EM, Lubock NB, Venkatakrishnan AJ, et al. Structural and functional characterization of G protein-coupled receptors with deep mutational scanning. Elife. 2020;9:e54895. doi: 10.7554/eLife.54895.
   PubMed Web of Science ®Google Scholar
• Wan A, Place E, Pierce EA, et al. Characterizing variants of unknown significance in rhodopsin: a functional genomics approach. Hum Mutat. 2019;40(8):1127–1144. doi: 10.1002/humu.23762.
   PubMed Web of Science ®Google Scholar
• Waheed NK, Qavi AH, Malik SN, et al. A nonsense mutation in S-antigen (p.Glu306*) causes Oguchi disease. Mol Vis. 2012;18:1253–1259.
   Google Scholar
• Fuchs S, Nakazawa M, Maw M, et al. A homozygous 1-base pair deletion in the Arrestin gene is a frequent cause of Oguchi disease in Japanese. Nat Genet. 1995;10(3):360–362. doi: 10.1038/ng0795-360.
   PubMed Web of Science ®Google Scholar
• Iiri T, Herzmark P, Nakamoto JM, et al. Rapid gdp release from G(S-alpha) in patients with gain and loss of endocrine function. Nature. 1994;371(6493):164–168. doi: 10.1038/371164a0.
   PubMed Web of Science ®Google Scholar
• Gromoll J, Schulz A, Borta H, et al. Homozygous mutation within the conserved Ala-Phe-Asn-Glu-Thr motif of exon 7 of the LH receptor causes male pseudohermaphroditism. Eur J Endocrinol. 2002;147(5):597–608. doi: 10.1530/eje.0.1470597.
   PubMed Web of Science ®Google Scholar
• Althumairy A, Zhang X, Baez N, et al. Glycoprotein G-protein coupled receptors in disease: luteinizing hormone receptors and follicle stimulating hormone receptors. Diseases. 2020;8(3):35. doi: 10.3390/diseases8030035.
   PubMedGoogle Scholar
• Casas-González P, Scaglia HE, Pérez-Solís MA, et al. Normal testicular function without detectable follicle-stimulating hormone. A novel mutation in the follicle stimulating hormone receptor gene leading to apparent constitutive activity and impaired agonist-induced desensitization and internalization. Mol Cell Endocrinol. 2012;364(1-2):71–82. doi: 10.1016/j.mce.2012.08.011.
   PubMed Web of Science ®Google Scholar
• Kosugi K, Van Dop C, Geffner ME, et al. Characterization of heterogeneous mutations causing constitutive activation of the luteinizing hormone receptor in familial male precocious puberty. Hum Mol Genet. 2017;4(2):183–188. doi: 10.1093/hmg/4.2.183.
   Google Scholar
• Topaloğlu AK. Update on the genetics of idiopathic hypogonadotropic hypogonadism. J Clin Res Pediatr Endocrinol. 2017;9(Suppl 2):113–122. doi: 10.4274/jcrpe.2017.S010.
   PubMed Web of Science ®Google Scholar
• Zhao Y, Wu J, Wang X, et al. Prokineticins and their G protein-coupled receptors in health and disease. Prog Mol Biol Transl Sci. 2019;161:149–179.
   PubMed Web of Science ®Google Scholar
• de Roux N, Genin E, Carel JC, et al. Hypogonadotropic hypogonadism due to loss of function of the KiSS1-derived peptide receptor GPR54. Proc Natl Acad Sci U S A. 2003;100(19):10972–10976. doi: 10.1073/pnas.1834399100.
   PubMed Web of Science ®Google Scholar
• Franco B, Guioli S, Pragliola A, et al. A gene deleted in kallmanns syndrome shares homology with neural cell-adhesion and axonal path-fi nding molecules. Nature. 1991;353(6344):529–536. doi: 10.1038/353529a0.
   PubMed Web of Science ®Google Scholar
• Legouis R, Hardelin JP, Levilliers J, et al. The candidate gene for the X-linked kallmann syndrome encodes a protein related to adhesion molecules. Cell. 1991;67(2):423–435. doi: 10.1016/0092-8674(91)90193-3.
   PubMed Web of Science ®Google Scholar
• Habiby RL, Boepple P, Nachtigall L, et al. Adrenal hypoplasia congenita with hypogonadotropic hypogonadism—evidence that DAX-1 mutations lead to combined hypothalamic and pituitary defects in gonadotropin production. J Clin Invest. 1996;98(4):1055–1062. doi: 10.1172/JCI118866.
   PubMed Web of Science ®Google Scholar
• Cham G, O'Brien B, Kimble RM. Idiopathic hypogonadotropic hypogonadism: a rare cause of primary amenorrhoea in adolescence-a review and update on diagnosis, management and advances in genetic understanding. BMJ Case Rep. 2021;14(4):e239495. doi: 10.1136/bcr-2020-239495.
   PubMedGoogle Scholar
• Monnier C, Dodé C, Fabre L, et al. PROKR2 missense mutations associated with kallmann syndrome impair receptor signalling activity. Hum Mol Genet. 2009;18(1):75–81. doi: 10.1093/hmg/ddn318.
   PubMed Web of Science ®Google Scholar
• Topaloglu AK, Reimann F, Guclu M, et al. TAC3 and TACR3 mutations in familial hypogonadotropic hypogonadism reveal a key role for neurokinin B in the Central control of reproduction. Nat Genet. 2009;41(3):354–358. doi: 10.1038/ng.306.
   PubMed Web of Science ®Google Scholar
• de Roux N, Young J, Misrahi M, et al. A family with hypogonadotropic hypogonadism and mutations in the gonadotropin-releasing hormone receptor. N Engl J Med. 1997;337(22):1597–1602. doi: 10.1056/NEJM199711273372205.
   PubMed Web of Science ®Google Scholar
• Layman LC, Cohen DP, Jin M, et al. Mutations in gonadotropin-releasing hormone receptor gene cause hypogonadotropic hypogonadism. Nat Genet. 1998;18(1):14–15. doi: 10.1038/ng0198-14.
   PubMed Web of Science ®Google Scholar
• Ahmad S, Ali MZ, Abbasi SW, et al. A GHRHR founder mutation causes isolated growth hormone deficiency type IV in a consanguineous pakistani family. Front Endocrinol (Lausanne). 2023;14:1066182. doi: 10.3389/fendo.2023.1066182.
   PubMed Web of Science ®Google Scholar
• Finch AR, Caunt CJ, Armstrong SP, et al. Plasma membrane expression of gonadotropin-releasing hormone receptors: regulation by peptide and nonpeptide antagonists. Mol Endocrinol. 2010;24(2):423–435. doi: 10.1210/me.2009-0343.
   PubMedGoogle Scholar
• Martin TJ, Sims NA, Seeman E. Physiological and pharmacological roles of PTH and PTHrP in bone using their shared receptor, PTH1R. Endocr Rev. 2021;42(4):383–406. doi: 10.1210/endrev/bnab005.
   PubMed Web of Science ®Google Scholar
• Ewers M, Canaff L, Weh AE, et al. The three common polymorphisms p.A986S, p.R990G and p.Q1011E in the calcium sensing receptor (CASR) are not associated with chronic pancreatitis. Pancreatology. 2021;21(7):1299–1304. doi: 10.1016/j.pan.2021.08.008.
   PubMed Web of Science ®Google Scholar
• Stepanchick A, McKenna J, McGovern O, et al. Calcium sensing receptor mutations implicated in pancreatitis and idiopathic epilepsy syndrome disrupt an arginine-rich retention motif. Cell Physiol Biochem. 2010;26(3):363–374. doi: 10.1159/000320560.
   PubMedGoogle Scholar
• Sutkeviciute I, Clark LJ, White AD, et al. PTH/PTHrP receptor signaling, allostery, and structures. Trends Endocrinol Metab. 2019;30(11):860–874. doi: 10.1016/j.tem.2019.07.011.
   PubMed Web of Science ®Google Scholar
• Saito H, Noda H, Gatault P, et al. Progression of mineral ion abnormalities in patients with jansen metaphyseal chondrodysplasia. J Clin Endocrinol Metab. 2018;103(7):2660–2669. doi: 10.1210/jc.2018-00332.
   PubMed Web of Science ®Google Scholar
• Noda H, Guo J, Khatri A, et al. An inverse agonist ligand of the PTH receptor partially rescues skeletal defects in a mouse model of jansen’s metaphyseal chondrodysplasia. J Bone Miner Res. 2020;35(3):540–549. doi: 10.1002/jbmr.3913.
   PubMed Web of Science ®Google Scholar
• Hoogendam J, Farih-Sips H, Wÿnaendts LC, et al. Novel mutations in the parathyroid hormone (PTH)/PTH-related peptide receptor type 1 causing blomstrand osteochondrodysplasia types I and II. J Clin Endocrinol Metab. 2007;92(3):1088–1095. doi: 10.1210/jc.2006-0300.
   PubMed Web of Science ®Google Scholar
• Duchatelet S, Ostergaard E, Cortes D, et al. Recessive mutations in PTHR1 cause contrasting skeletal dysplasias in eiken and blomstrand syndromes. Hum Mol Genet. 2005;14(1):1–5. doi: 10.1093/hmg/ddi001.
   PubMed Web of Science ®Google Scholar
• Portales-Castillo I, Dean T, Cheloha RW, et al. Altered signaling and desensitization responses in PTH1R mutants associated with eiken syndrome. Commun Biol. 2023;6(1):599. doi: 10.1038/s42003-023-04966-0.
   PubMed Web of Science ®Google Scholar
• Duprez L, Parma J, Van Sande J, et al. Germline mutations in the thyrotropin receptor gene cause non-autoimmune autosomal dominant hyperthyroidism. Nat Genet. 1994;7(3):396–401. doi: 10.1038/ng0794-396.
   PubMed Web of Science ®Google Scholar
• Arturi F, Capula C, Chiefari E, et al. Thyroid hyperfunctioning adenomas with and without gsp/TSH receptor mutations show similar clinical features. Exp Clin Endocrinol Diabetes. 1998;106(3):234–236. doi: 10.1055/s-0029-1211982.
   PubMed Web of Science ®Google Scholar
• Larrivée-Vanier S, Magne F, Hamdoun E, et al. Severe congenital hypothyroidism due to a novel deep intronic mutation in the TSH receptor gene causing intron retention. J Endocr Soc. 2020;5(3):bvaa183. doi: 10.1210/jendso/bvaa183.
   PubMed Web of Science ®Google Scholar
• Biebermann H, Schoneberg T, Hess C, et al. The first activating TSH receptor mutation in transmembrane domain 1 identified in a family with nonautoimmune hyperthyroidism. J Clin Endocrinol Metab. 2001;86(9):4429–4433. doi: 10.1210/jcem.86.9.7888.
   PubMed Web of Science ®Google Scholar
• Jordan N, Williams N, Gregory JW, et al. The W546X mutation of the thyrotropin receptor gene: potential major contributor to thyroid dysfunction in a caucasian population. J Clin Endocrinol Metab. 2003;88(3):1002–1005. doi: 10.1210/jc.2002-021301.
   PubMed Web of Science ®Google Scholar
• Biebermann H, Winkler F, Kleinau G. Genetic defects, thyroid growth and malfunctions of the TSHR in pediatric patients. Front Biosci (Landmark Ed). 2010;15(3):913–933. doi: 10.2741/3654.
   PubMedGoogle Scholar
• Hébrant A, Van Staveren WCG, Maenhaut C, et al. Genetic hyperthyroidism: hyperthyroidism due to activating TSHR mutations. Eur J Endocrinol. 2011;164(1):1–9. doi: 10.1530/EJE-10-0775.
   PubMed Web of Science ®Google Scholar
• Gabriel EM, Bergert ER, Grant CS, et al. Germline polymorphism of codon 727 of human thyroid-stimulating hormone receptor is associated with toxic multinodular goiter. J Clin Endocrinol Metab. 1999;84(9):3328–3335. doi: 10.1210/jc.84.9.3328.
   PubMed Web of Science ®Google Scholar
• Biebermann H, Schoneberg T, Krude H, et al. Constitutively activating TSH receptor mutations as a molecular cause of non-autoimmune hyperthyroidism in childhood. Langenbecks Arch Surg. 2000;385(6):390–392. doi: 10.1007/s004230000145.
   PubMed Web of Science ®Google Scholar
• Karges B, Krause G, Homoki J, et al. TSH receptor mutation V509A causes familial hyperthyroidism by release of interhelical constraints between transmembrane helices TMH3 and TMH5. J Endocrinol. 2005;186(2):377–385. doi: 10.1677/joe.1.06208.
   PubMed Web of Science ®Google Scholar
• Tonacchera M, Agretti P, Chiovato L, et al. Activating thyrotropin receptor mutations are present in nonadenomatous hyperfunctioning nodules of toxic or autonomous multinodular goiter. J Clin Endocrinol Metab. 2000;85(6):2270–2274. doi: 10.1210/jcem.85.6.6634.
   PubMed Web of Science ®Google Scholar
• Lueblinghoff J, Eszlinger M, Jaeschke H, et al. Shared sporadic and somatic thyrotropin receptor mutations display more active in vitro activities than familial thyrotropin receptor mutations. Thyroid. 2011;21(3):221–229. doi: 10.1089/thy.2010.0312.
   PubMed Web of Science ®Google Scholar
• Boelen A, Kwakkel J, Fliers E. Thyroid hormone receptors in health and disease. Minerva Endocrinol. 2012;37(4):291–304.
   PubMed Web of Science ®Google Scholar
• Marín-Sánchez A, Álvarez-Sierra D, González O, et al. Regulation of TSHR expression in the thyroid and thymus may contribute to TSHR tolerance failure in graves’ disease patients via two distinct mechanisms. Front Immunol. 2019;10:1695. doi: 10.3389/fimmu.2019.01695.
   PubMed Web of Science ®Google Scholar
• Brand OJ, Barrett JC, Simmonds MJ, et al. Association of the thyroid stimulating hormone receptor gene (TSHR) with Graves’ disease. Hum Mol Genet. 2009;18(9):1704–1713. doi: 10.1093/hmg/ddp087.
   PubMed Web of Science ®Google Scholar
• Noel SD, Kaiser UB. G protein-coupled receptors involved in GnRH regulation: molecular insights from human disease. Mol Cell Endocrinol. 2011;346(1-2):91–101. doi: 10.1016/j.mce.2011.06.022.
   PubMed Web of Science ®Google Scholar
• Zhang R, Linpeng S, Li Z, et al. Deficiency in GnRH receptor trafficking due to a novel homozygous mutation causes idiopathic hypogonadotropic hypogonadism in three prepubertal siblings. Gene. 2018;669:42–46. doi: 10.1016/j.gene.2018.05.050.
   PubMed Web of Science ®Google Scholar
• Wang L, Lin W, Li X, et al. A case report of congenital idiopathic hypogonadotropic hypogonadism caused by novel mutation of GNRHR gene. Medicine (Baltimore). 2021;2021;100(5):e24007. doi: 10.1097/MD.0000000000024007.
   PubMed Web of Science ®Google Scholar
• Chen Y, Sun T, Niu Y, et al. A partial loss-of-function variant in GNRNR gene in a chinese cohort with idiopathic hypogonadotropic hypogonadism. Transl Androl Urol. 2021;10(4):1676–1687. doi: 10.21037/tau-20-1390.
   PubMed Web of Science ®Google Scholar
• Spanakis E, Milord E, Gragnoli C. AVPR2 variants and mutations in nephrogenic diabetes insipidus: review and missense mutation significance. J Cell Physiol. 2008;217(3):605–617. doi: 10.1002/jcp.21552.
   PubMed Web of Science ®Google Scholar
• Bichet DG, El Tarazi A, Matar J, et al. Aquaporin-2: new mutations responsible for autosomal recessive nephrogenic diabetes insipidus—update and epidemiology. Clin Kidney J. 2012;5(3):195–202. doi: 10.1093/ckj/sfs029.
   PubMedGoogle Scholar
• Rosenthal W, Seibold A, Antaramian A, et al. Molecular identification of the gene responsible for congenital nephrogenic diabetes insipidus. Nature. 1992;359(6392):233–235. doi: 10.1038/359233a0.
   PubMed Web of Science ®Google Scholar
• Feinstein TN, Yui N, Webber MJ, et al. Noncanonical control of vasopressin receptor type 2 signaling by retromer and arrestin. J Biol Chem. 2013;288(39):27849–27860. doi: 10.1074/jbc.M112.445098.
   PubMed Web of Science ®Google Scholar
• Los EL, Deen PM, Robben JH. Potential of nonpeptide (ant)agonists to rescue vasopressin V2 receptor mutants for the treatment of X-linked nephrogenic diabetes insipidus. J Neuroendocrinol. 2010;22(5):393–399. doi: 10.1111/j.1365-2826.2010.01983.x.
   PubMed Web of Science ®Google Scholar
• McKusick VA. Mendelian inheritance in man and its online version, OMIM. Am J Hum Genet. 2007;80(4):588–604. doi: 10.1086/514346.
   PubMed Web of Science ®Google Scholar
• Fujiwara TM, Bichet DG. Molecular biology of hereditary diabetes insipidus. J Am Soc Nephrol. 2005;16(10):2836–2846. doi: 10.1681/ASN.2005040371.
   PubMed Web of Science ®Google Scholar
• Arthus M-F, Lonergan M, Crumley MJ, et al. Report of 33 novel AVPR2 mutations and analysis of 117 families with X-linked nephrogenic diabetes insipidus. J Am Soc Nephrol. 2000;11(6):1044–1054. doi: 10.1681/ASN.V1161044.
   PubMed Web of Science ®Google Scholar
• Nomura Y, Onigata K, Nagashima T, et al. Detection of skewed X-inactivation in two female carriers of vasopressin type 2 receptor gene mutation. J Clin Endocrinol Metab. 1997;82(10):3434–3437. doi: 10.1210/jcem.82.10.4312.
   PubMed Web of Science ®Google Scholar
• Bichet DG, Arthus M-F, Lonergan M, et al. X-linked nephrogenic diabetes insipidus mutations in North america and the hopewell hypothesis. J Clin Invest. 1993;92(3):1262–1268. doi: 10.1172/JCI116698.
   PubMed Web of Science ®Google Scholar
• Hobbs HH, Russell DW, Brown MS, et al. The LDL receptor locus in familial hypercholesterolemia: mutational analysis of a membrane protein. Annu Rev Genet. 1990;24(1):133–170. doi: 10.1146/annurev.ge.24.120190.001025.
   PubMedGoogle Scholar
• Wuller S, Wiesner B, Loffl Er A, et al. Pharmacochaperones post-translationally enhance cell surface expression by increasing conformational stability of wild-type and mutant vasopressin V2 receptors. J Biol Chem. 2004;279(45):47254–47263. doi: 10.1074/jbc.M408154200.
   PubMed Web of Science ®Google Scholar
• Hermosilla R, Oueslati M, Donalies U, et al. Disease-causing V(2) vasopressin receptors are retained in different compartments of the early secretory pathway. Traffic. 2004;5(12):993–1005. doi: 10.1111/j.1600-0854.2004.00239.x.
   PubMed Web of Science ®Google Scholar
• Bernier V, Morello JP, Zarruk A, et al. Pharmacologic chaperones as a potential treatment for X-linked nephrogenic diabetes insipidus. J Am Soc Nephrol. 2006;17(1):232–243. doi: 10.1681/ASN.2005080854.
   PubMed Web of Science ®Google Scholar
• Morello JP, Salahpour A, Laperrière A, et al. Pharmacological chaperones rescue cell-surface expression and function of misfolded V2 vasopressin receptor mutants. J Clin Invest. 2000;105(7):887–895. doi: 10.1172/JCI8688.
   PubMed Web of Science ®Google Scholar
• Schoneberg T, Schulz A, Biebermann H, et al. Mutant G-protein-coupled receptors as a cause of human diseases. Pharmacol Ther. 2004;104(3):173–206. doi: 10.1016/j.pharmthera.2004.08.008.
   PubMed Web of Science ®Google Scholar
• Romisch K. A cure for traffic jams: small molecule chaperones in the endoplasmic reticulum. Traffic. 2004;5(11):815–820. doi: 10.1111/j.1600-0854.2004.00231.x.
   PubMed Web of Science ®Google Scholar
• Tamarappoo BK, Verkman AS. Defective aquaporin-2 trafficking in nephrogenic diabetes insipidus and correction by chemical chaperones. J Clin Invest. 1998;101(10):2257–2267. doi: 10.1172/JCI2303.
   PubMed Web of Science ®Google Scholar
• Kunchaparty S, Palcso M, Berkman J, et al. Defective processing and expression of thiazide-sensitive Na-Cl cotransporter as a cause of gitelman’s syndrome. Am J Physiol. 1999;277(4):F643–F649. doi: 10.1152/ajprenal.1999.277.4.F643.
   PubMedGoogle Scholar
• Hayama A, Rai T, Sasaki S, et al. Molecular mechanisms of bartter syndrome caused by mutations in the BSND gene. Histochem Cell Biol. 2003;119(6):485–493. doi: 10.1007/s00418-003-0535-2.
   PubMed Web of Science ®Google Scholar
• Peters M, Ermert S, Jeck N, et al. Classification and rescue of ROMK mutations underlying hyperprostaglandin E syndrome/antenatal bartter syndrome. Kidney Int. 2003;64(3):923–932. doi: 10.1046/j.1523-1755.2003.00153.x.
   PubMed Web of Science ®Google Scholar
• Chillaron J, Estevez R, Samarzija I, et al. An intracellular trafficking defect in type I cystinuria rBAT mutants M467T and M467K. J Biol Chem. 1997;272(14):9543–9549. doi: 10.1074/jbc.272.14.9543.
   PubMed Web of Science ®Google Scholar
• Bonnardeaux A, Bichet DG. Inherited disorders of the renal tubule. In: Taal MW, Chertow GM, Marsden PA, Sko K, Yu ASL, Brenner BM, editors. Brenner & rector’s the kidney. Vol. 2. 9th ed. Philadelphia (PA): Elsevier Saunders; 2012:1584–1625.
   Google Scholar
• Lomas DA, Evans DL, Finch JT, et al. The mechanism of Z alpha 1-antitrypsin accumulation in the liver. Nature. 1992;357(6379):605–607. doi: 10.1038/357605a0.
   PubMed Web of Science ®Google Scholar
• Lawless MW, Greene CM, Mulgrew A, et al. Activation of endoplasmic reticulum specific stress responses associated with the conformational disease Z alpha 1-antitrypsin deficiency. J Immunol. 2004;172(9):5722–5726. doi: 10.4049/jimmunol.172.9.5722.
   PubMed Web of Science ®Google Scholar
• Cohen FE, Kelly JW. Therapeutic approaches to protein-misfolding diseases. Nature. 2003;426(6968):905–909. doi: 10.1038/nature02265.
   PubMed Web of Science ®Google Scholar
• Ulloa-Aguirre A, Janovick JA, Brothers SP, et al. Pharmacologic rescue of conformationally- defective proteins: implications for the treatment of human disease. Traffic. 2004;5(11):821–837. doi: 10.1111/j.1600-0854.2004.00232.x.
   PubMed Web of Science ®Google Scholar
• Bernier V, Lagace M, Lonergan M, et al. Functional rescue of the constitutively internalized V2 vasopressin receptor mutant R137H by the pharmacological chaperone action of SR49059. Mol Endocrinol. 2004;18(8):2074–2084. doi: 10.1210/me.2004-0080.
   PubMedGoogle Scholar
• Barak LS, Oakley RH, Laporte SA, et al. Constitutive arrestin-mediated desensitization of a human vasopressin receptor mutant associated with nephrogenic ­diabetes insipidus. Proc Natl Acad Sci U S A. 2001;98(1):93–98. doi: 10.1073/pnas.98.1.93.
   PubMed Web of Science ®Google Scholar
• Soule S, Florkowski C, Potter H, et al. Intermittent severe, symptomatic hyponatraemia due to the nephrogenic syndrome of inappropriate antidiuresis. Ann Clin Biochem. 2008;45(Pt 5):520–523. doi: 10.1258/acb.2007.007211.
   PubMedGoogle Scholar
• Feldman BJ, Rosenthal SM, Vargas GA, et al. Nephrogenic syndrome of inappropriate antidiuresis. N Engl J Med. 2005;352(18):1884–1890. doi: 10.1056/NEJMoa042743.
   PubMed Web of Science ®Google Scholar
• Marcialis MA, Faa V, Fanos V, et al. Neonatal onset of nephrogenic syndrome of inappropriate antidiuresis. Pediatr Nephrol. 2008;23(12):2267–2271. doi: 10.1007/s00467-008-0913-z.
   PubMed Web of Science ®Google Scholar
• Zhang Y-J, Li D-J, Li Z-Y, et al. Influence of genetic polymorphisms in P2Y12 receptor signaling pathway on antiplatelet response to clopidogrel in coronary heart disease. BMC Cardiovasc Disord. 2022;22(1):575. doi: 10.1186/s12872-022-02988-w.
   PubMed Web of Science ®Google Scholar
• Hofstra RM, Osinga J, Tan-Sindhunata G, et al. A homozygous mutation in the endothelin-3 gene associated with a combined waardenburg type 2 and hirschsprung phenotype (Shah-Waardenburg syndrome). Nat Genet. 1996;12(4):445–447. doi: 10.1038/ng0496-445.
   PubMed Web of Science ®Google Scholar
• Hofstra RMW, Valdenaire O, Arch E, et al. A loss-of-function mutation in the endothelin-converting enzyme 1 (ECE-1) associated with hirschsprung disease, cardiac defects, and autonomic dysfunction. Am J Hum Genet. 1999;64(1):304–308. doi: 10.1086/302184.
   PubMed Web of Science ®Google Scholar
• Fuchs S, Amiel J, Claudel S, et al. Functional characterization of three mutations of the endothelin B receptor gene in patients with hirschsprung’s disease: evidence for selective loss of G(i) coupling. Mol Med. 2001;7(2):115–124. doi: 10.1007/BF03401945.
   PubMed Web of Science ®Google Scholar
• Li H, Lou R, Xu X, et al. The variations in human orphan G protein-coupled receptor QRFPR affect PI3K-AKT-mTOR signaling. J Clin Lab Anal. 2021;35(7):e23822. doi: 10.1002/jcla.23822.
   PubMed Web of Science ®Google Scholar
• Brown EM. Role of the calcium-sensing receptor in extracellular calcium homeostasis. Best Pract Res Clin Endocrinol Metab. 2013;27(3):333–343. doi: 10.1016/j.beem.2013.02.006.
   PubMed Web of Science ®Google Scholar
• Deng X, Xin Y, Miller CL, et al. Structural mechanism of cooperative regulation of calcium-sensing receptor-mediated cellular signaling. Curr Opin Physiol. 2020;17:269–277. doi: 10.1016/j.cophys.2020.08.020.
   PubMed Web of Science ®Google Scholar
• Gao Y, Robertson MJ, Rahman SN, et al. Asymmetric activation of the calcium-sensing receptor homodimer. Nature. 2021;595(7867):455–459. doi: 10.1038/s41586-021-03691-0.
   PubMed Web of Science ®Google Scholar
• Gorvin CM. Molecular and clinical insights from studies of calcium-sensing receptor mutations. J Mol Endocrinol. 2019;63(2):R1–R16. doi: 10.1530/JME-19-0104.
   PubMed Web of Science ®Google Scholar
• Pidasheva S, D'Souza-Li L, Canaff L, et al. CASRdb: calcium-sensing receptor locus-specific database for mutations causing familial (benign) hypocalciuric hypercalcemia, neonatal severe hyperparathyroidism, and autosomal dominant hypocalcemia. Hum Mutat. 2004;24(2):107–111. doi: 10.1002/humu.20067.
   PubMed Web of Science ®Google Scholar
• Marx SJ, Sinaii N. Neonatal severe hyperparathyroidism: novel insights from calcium, PTH, and the CASR gene. J Clin Endocrinol Metab. 2020;105(4):1061–1078. doi: 10.1210/clinem/dgz233.
   PubMed Web of Science ®Google Scholar
• Christensen SE, Nissen PH, Vestergaard P, et al. Discriminative power of three indices of renal calcium excretion for the distinction between familial hypocalciuric hypercalcaemia and primary hyperparathyroidism: a follow-up study on methods. Clin Endocrinol (Oxf). 2008;69(5):713–720. doi: 10.1111/j.1365-2265.2008.03259.x.
   PubMed Web of Science ®Google Scholar
• Roszko KL, Stapleton Smith LM, Sridhar AV, et al. Autosomal dominant hypocalcemia type 1: a systematic review. J Bone Miner Res. 2022;37(10):1926–1935. doi: 10.1002/jbmr.4659.
   PubMed Web of Science ®Google Scholar
• Marx SJ. Calcimimetic use in familial hypocalciuric hypercalcemia-A perspective in endocrinology. J Clin Endocrinol Metab. 2017;102(11):3933–3936. doi: 10.1210/jc.2017-01606.
   PubMed Web of Science ®Google Scholar
• Vahe C, Benomar K, Espiard S, et al. Diseases associated with calcium-sensing receptor. Orphanet J Rare Dis. 2017;12(1):19. doi: 10.1186/s13023-017-0570-z.
   PubMedGoogle Scholar
• Roberts MS, Gafni RI, Brillante B, et al. Treatment of autosomal dominant hypocalcemia type 1 with the calcilytic NPSP795 (SHP635). J Bone Miner Res. 2019;34(9):1609–1618. doi: 10.1002/jbmr.3747.
   PubMed Web of Science ®Google Scholar
• Hannan FM, Babinsky VN, Thakker RV. Disorders of the calcium-sensing receptor and partner proteins: insights into the molecular basis of calcium homeostasis. J Mol Endocrinol. 2016;57(3):R127–R142. doi: 10.1530/JME-16-0124.
   PubMed Web of Science ®Google Scholar
• Mayr B, Schnabel D, Dörr H-G, et al. Genetics in endocrinology: gain and loss of function mutations of the calcium-sensing receptor and associated proteins: current treatment concepts. Eur J Endocrinol. 2016;174(5):R189–R208. doi: 10.1530/EJE-15-1028.
   PubMed Web of Science ®Google Scholar
• Roszko KL, Bi RD, Mannstadt M. Autosomal dominant hypocalcemia (hypoparathyroidism) types 1 and 2. Front Physiol. 2016;7:458. doi: 10.3389/fphys.2016.00458.
   PubMed Web of Science ®Google Scholar
• Obermannova B, Sumnik Z, Dusatkova P, et al. Novel calcium-sensing receptor cytoplasmic tail deletion mutation causing autosomal dominant hypocalcemia: molecular and clinical study. Eur J Endocrinol. 2016;174(4):K1–K11. doi: 10.1530/EJE-15-1216.
   PubMed Web of Science ®Google Scholar
• Cavaco BM, Canaff L, Nolin-Lapalme A, et al. Homozygous calcium-sensing receptor polymorphism R544Q presents as hypocalcemic hypoparathyroidism. J Clin Endocrinol Metab. 2018;103(8):2879–2888. doi: 10.1210/jc.2017-02407.
   PubMed Web of Science ®Google Scholar
• Leach K, Wen A, Davey AE, et al. Identification of molecular phenotypes and biased signaling induced by naturally occurring mutations of the human calcium-sensing receptor. Endocrinology. 2012;153(9):4304–4316. doi: 10.1210/en.2012-1449.
   PubMed Web of Science ®Google Scholar
• Gorvin CM, Frost M, Malinauskas T, et al. Calcium-sensing receptor residues with loss- and gain-of-function mutations are located in regions of conformational change and cause signalling bias. Hum Mol Genet. 2018;27(21):3720–3733. doi: 10.1093/hmg/ddy263.
   PubMed Web of Science ®Google Scholar
• Makita N, Ando T, Sato J, et al. Cinacalcet corrects biased allosteric modulation of CaSR by AHH autoantibody. JCI Insight. 2019;4(8):e126449. doi: 10.1172/jci.insight.126449.
   PubMed Web of Science ®Google Scholar
• Gorvin CM, Rogers A, Hastoy B, et al. AP2 sigma mutations impair calcium-sensing receptor trafficking and signaling, and show an endosomal pathway to spatially direct G-protein selectivity. Cell Rep. 2018;22(4):1054–1066. doi: 10.1016/j.celrep.2017.12.089.
   PubMed Web of Science ®Google Scholar
• Dershem R, Gorvin CM, Metpally RPR, et al. Familial hypocalciuric hypercalcemia type 1 and autosomal-dominant hypocalcemia type 1: prevalence in a large healthcare population. Am J Hum Genet. 2020;106(6):734–747. doi: 10.1016/j.ajhg.2020.04.006.
   PubMed Web of Science ®Google Scholar
• Cerani A, Zhou S, Forgetta V, et al. Genetic predisposition to increased serum calcium, bone mineral density, and fracture risk in individuals with normal calcium levels: mendelian randomisation study. BMJ. 2019;366:l4410. doi: 10.1136/bmj.l4410.
   PubMedGoogle Scholar
• Guerreiro R, Brás J, Batista S, et al. Pseudohypoparathyroidism type I-b with neurological involvement is associated with a homozygous PTH1R mutation. Genes Brain Behav. 2016;15(7):669–677. doi: 10.1111/gbb.12308.
   PubMed Web of Science ®Google Scholar
• Couvineau A, Wouters V, Bertrand G, et al. PTHR1 mutations associated with ollier disease result in receptor loss of function. Hum Mol Genet. 2008;17(18):2766–2775. doi: 10.1093/hmg/ddn176.
   PubMed Web of Science ®Google Scholar
• Roth H, Fritsche LG, Meier C, et al. Expanding the spectrum of PTH1R mutations in patients with primary failure of tooth eruption. Clin Oral Investig. 2014;18(2):377–384. doi: 10.1007/s00784-013-1014-3.
   PubMed Web of Science ®Google Scholar
• Thompson MD, Sakurai T, Rainero I, et al. Orexin receptor multimerization versus functional interactions: neuropharmacological implications for opioid and cannabinoid signalling and pharmacogenetics. Pharmaceuticals (Basel). 2017;10(4):79. doi: 10.3390/ph10040079.
   PubMedGoogle Scholar
• Calbet-Llopart N, Combalia M, Kiroglu A, et al. Common genetic variants associated with melanoma risk or naevus count in patients with wildtype MC1R melanoma. Br J Dermatol. 2022;187(5):753–764. doi: 10.1111/bjd.21707.
   Google Scholar
• Tao Y-X. The melanocortin-4 receptor: physiology, pharmacology, and pathophysiology. Endocr Rev. 2010;31(4):506–543. doi: 10.1210/er.2009-0037.
   PubMed Web of Science ®Google Scholar
• Hinney A, Volckmar A-L, Knoll N. Melanocortin-4 receptor in energy homeostasis and obesity pathogenesis. Prog Mol Biol Transl Sci. 2013;114:147–191. doi: 10.1016/B978-0-12-386933-3.00005-4.
   PubMed Web of Science ®Google Scholar
• Qin L, Tiwari AK, Zai CC, et al. Regulation of melanocortin-4-receptor (MC4R) expression by SNP rs17066842 is dependent on glucose concentration. Eur Neuropsychopharmacol. 2020;37:39–48. doi: 10.1016/j.euroneuro.2020.05.008.
   PubMed Web of Science ®Google Scholar
• Yeo GSH, Farooqi IS, Aminian S, et al. A frameshift mutation in MC4R associated with dominantly inherited human obesity. Nat Genet. 1998;20(2):111–112. doi: 10.1038/2404.
   PubMed Web of Science ®Google Scholar
• Lubrano-Berthelier C, Le Stunff C, Bougneres P, et al. Clinical case seminar—a homozygous null mutation delineates the role of the melanocortin-4 receptor in humans. J Clin Endocrinol Metab. 2004;89(5):2028–2032. doi: 10.1210/jc.2003-031993.
   PubMed Web of Science ®Google Scholar
• Wade KH, Lam BYH, Melvin A, et al. Loss-of-function mutations in the melanocortin 4 receptor in a UK birth cohort. Nat Med. 2021;27(6):1088–1096. doi: 10.1038/s41591-021-01349-y.
   PubMed Web of Science ®Google Scholar
• Adan RAH, Kas MJH. Inverse agonism gains weight. Trends Pharmacol Sci. 2003;24(6):315–321. doi: 10.1016/S0165-6147(03)00130-5.
   PubMed Web of Science ®Google Scholar
• Clément K, van den Akker E, Argente J; Setmelanotide POMC and LEPR Phase 3 Trial Investigators., et al. Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials. Lancet Diabetes Endocrinol. 2020;8(12):960–970. doi: 10.1016/S2213-8587(20)30364-8.
   PubMed Web of Science ®Google Scholar
• Marsh DJ, Hollopeter G, Huszar D, et al. Response of melanocortin-4 receptor deficient mice to anorectic and orexigenic peptides. Nat Genet. 1999;21(1):119–122. doi: 10.1038/5070.
   PubMed Web of Science ®Google Scholar
• Branson R, Potoczna N, Kral JG, et al. Binge eating as a major phenotype of melanocortin 4 receptor gene mutations. N Engl J Med. 2003;348(12):1096–1103. doi: 10.1056/NEJMoa021971.
   PubMed Web of Science ®Google Scholar
• List JF, Habener JF. Defective melanocortin 4 receptors in hyperphagia and morbid obesity. N Engl J Med. 2003;348(12):1160–1163. doi: 10.1056/NEJMe030013.
   PubMed Web of Science ®Google Scholar
• Gaulton KJ, Ferreira T, Lee Y, DIAbetes Genetics Replication And Meta-analysis (DIAGRAM) Consortium., et al. Genetic fine mapping and genomic annotation defines causal mechanisms at type 2 diabetes susceptibility loci. Nat Genet. 2015;47(12):1415–1425. doi: 10.1038/ng.3437.
   PubMed Web of Science ®Google Scholar
• Vaisse C, Clement K, Durand E, et al. Melanocortin-4 receptor mutations are a frequent and heterogeneous cause of morbid obesity. J Clin Invest. 2000;106(2):253–262. doi: 10.1172/JCI9238.
   PubMed Web of Science ®Google Scholar
• Clément K, Mosbah H, Poitou C. Rare genetic forms of obesity: from gene to therapy. Physiol Behav. 2020;227:113–134.
   Web of Science ®Google Scholar
• Lotta LA, Mokrosiński J, Mendes de Oliveira E, et al. Human gain-of-function MC4R variants show signaling bias and protect against obesity. Cell. 2019;177(3):597–607.e9. doi: 10.1016/j.cell.2019.03.044.
   PubMed Web of Science ®Google Scholar
• Brouwers B, Mendes de Oliveira E, Marti-Solano M, et al. Human MC4R variants affect endocytosis, trafficking and dimerization revealing multiple cellular mechanisms involved in weight regulation. Cell Rep. 2021;34(12):108862. doi: 10.1016/j.celrep.2021.108862.
   PubMed Web of Science ®Google Scholar
• Weedon MN, Wright CF, Patel KA, et al. Unreliability of genotyping arrays for detecting very rare variants in human genetic studies: example from a recent study of MC4R. Cell. 2021;184(7):1651. doi: 10.1016/j.cell.2021.03.015.
   PubMed Web of Science ®Google Scholar
• Lotta L, Langenberg C, Wareham NJ, et al. Reply to unreliability of genotyping arrays for detecting very rare variants in human genetic studies: example from a recent study of MC4R. Cell. 2021;184(7):1652–1653. doi: 10.1016/j.cell.2021.03.014.
   PubMed Web of Science ®Google Scholar
• Piechowski CL, Rediger A, Lagemann C, et al. Inhibition of melanocortin-4 receptor dimerization by substitutions in intracellular loop 2. J Mol Endocrinol. 2013;51(1):109–118. doi: 10.1530/JME-13-0061.
   PubMed Web of Science ®Google Scholar
• Baron M, Maillet J, Huyvaert M, et al. Loss-of-function mutations in MRAP2 are pathogenic in hyperphagic obesity with hyperglycemia and hypertension. Nat Med. 2019;25(11):1733–1738. doi: 10.1038/s41591-019-0622-0.
   PubMed Web of Science ®Google Scholar
• Berruien NNA, Smith CL. Emerging roles of melanocortin receptor accessory proteins (MRAP and MRAP2) in physiology and pathophysiology. Gene. 2020;757:144949. doi: 10.1016/j.gene.2020.144949.
   PubMed Web of Science ®Google Scholar
• Spana C, Jordan R, Fischkoff S. Of bremelanotide on body weight of obese women: data from two phase 1 randomized controlled trials. Diabetes Obes Metab. 2022Effect;24(6):1084–1093. doi: 10.1111/dom.14672.
   PubMed Web of Science ®Google Scholar
• Tsigos C, Tsiotra P, Garibaldi LR, et al. Mutations of the ACTH receptor gene in a new family with isolated glucocorticoid deficiency. Mol Genet Metab. 2000;71(4):646–650. doi: 10.1006/mgme.2000.3090.
   PubMed Web of Science ®Google Scholar
• Metherell LA, Naville D, Halaby G, et al. Nonclassic lipoid congenital adrenal hyperplasia masquerading as familial glucocorticoid deficiency. J Clin Endocrinol Metab. 2009;94(10):3865–3871. doi: 10.1210/jc.2009-0467.
   PubMed Web of Science ®Google Scholar
• Marti-Solano M, Crilly SE, Malinverni D, et al. Combinatorial expression of GPCR isoforms affects signalling and drug responses. Nature. 2020;587(7835):650–656. doi: 10.1038/s41586-020-2888-2.
   PubMed Web of Science ®Google Scholar
• Alviggi C, Conforti A, Santi D, et al. Clinical relevance of genetic variants of gonadotrophins and their receptors in controlled ovarian stimulation: a systematic review and meta-analysis. Hum Reprod Update. 2018;24(5):599–614. doi: 10.1093/humupd/dmy019.
   PubMed Web of Science ®Google Scholar
• Gromoll J, Simoni M, Nieschlag E. An activating mutation of the follicle-stimulating hormone receptor autonomously sustains spermatogenesis in a hypophysectomized man. J Clin Endocrinol Metab. 1996;81(4):1367–1370. doi: 10.1210/jcem.81.4.8636335.
   PubMed Web of Science ®Google Scholar
• Ulloa-Aguirre A, Zariñán T, Dias JA, et al. Mutations in G protein-coupled receptors that impact receptor trafficking and reproductive function. Mol Cell Endocrinol. 2014;382(1):411–423. doi: 10.1016/j.mce.2013.06.024.
   PubMed Web of Science ®Google Scholar
• De LA, Montanelli L, Van DJ, et al. Presence and absence of follicle-stimulating hormone receptor mutations provide some insights into spontaneous ovarian hyperstimulation syndrome physiopathology. J Clin Endocrinol Metab. 2006;91(2):555–562. doi: 10.1210/jc.2005-1580.
   PubMed Web of Science ®Google Scholar
• Meehan TP, Narayan P. Constitutively active luteinizing hormone receptors: consequences of in vivo expression. Mol Cell Endocrinol. 2007;260-262:294–300. doi: 10.1016/j.mce.2006.03.045.
   PubMed Web of Science ®Google Scholar
• Decaux G, Vandergheynst F, Bouko Y, et al. Nephrogenic syndrome of inappropriate antidiuresis in adults: high phenotypic variability in men and women from a large pedigree. J Am Soc Nephrol. 2007;18(2):606–612. doi: 10.1681/ASN.2006090987.
   PubMed Web of Science ®Google Scholar
• Carpentier E, Greenbaum LA, Rochdi D, et al. Identification and characterization of an activating F229V substitution in the V2 vasopressin receptor in an infant with NSIAD. J Am Soc Nephrol. 2012;23(10):1635–1640. doi: 10.1681/ASN.2012010077.
   PubMed Web of Science ®Google Scholar
• Bous J, Orcel H, Floquet N, et al. Cryo-electron microscopy structure of the antidiuretic hormone arginine-vasopressin V2 receptor signaling complex. Sci Adv. 2021;7(21):eabg5628. doi: 10.1126/sciadv.abg5628.
   PubMed Web of Science ®Google Scholar
• Kocan M, See HB, Sampaio NG, et al. Agonist-independent interactions between beta-arrestins and mutant vasopressin type II receptors associated with nephrogenic syndrome of inappropriate antidiuresis. Mol Endocrinol. 2009;23(4):559–571. doi: 10.1210/me.2008-0321.
   PubMedGoogle Scholar
• Ballesteros JA, Weinstein H. Integrated methods for the construction of three-dimensional models and computational probing of structure-function relations in G protein-coupled receptors. Methods Neurosci. 1995;25:366–428.
   Google Scholar
• Brooks A, Oostra BA, Hofstra RM. Studying the genetics of hirschsprung’s disease: unraveling an oligogenic disorder. Clin Genet. 2005;67(1):6–14. doi: 10.1111/j.1399-0004.2004.00319.x.
   PubMed Web of Science ®Google Scholar
• Sánchez-Mejías A, Fernández RM, López Alonso M, et al. New roles of EDNRB and EDN3 in the pathogenesis of hirschsprung disease. Genet Med. 2010;12(1):39–43. doi: 10.1097/GIM.0b013e3181c371b0.
   PubMed Web of Science ®Google Scholar
• Puffenberger EG, Hosoda K, Washington SS, et al. A missense mutation of the endothelin- B receptor gene in multigenic hirschsprung’s disease. Cell. 1994;79(7):1257–1266. doi: 10.1016/0092-8674(94)90016-7.
   PubMed Web of Science ®Google Scholar
• Imamura F, Arimoto I, Fujiyoshi Y, et al. W276 mutation in the endothelin receptor subtype B impairs G(q) but not G(i) or G(o) coupling. Biochemistry. 2000;39(4):686–692. doi: 10.1021/bi991981z.
   PubMed Web of Science ®Google Scholar
• Attie T, Till M, Pelet A, et al. Mutation of the endothelin-receptor-B gene in Waardenburg-Hirschsprung-disease. Hum Mol Genet. 1995;4(12):2407–2409. doi: 10.1093/hmg/4.12.2407.
   PubMed Web of Science ®Google Scholar
• Hollopeter G, Jantzen HM, Vincent D, et al. Identification of the platelet ADP receptor targeted by antithrombotic drugs. Nature. 2001;409(6817):202–207. doi: 10.1038/35051599.
   PubMed Web of Science ®Google Scholar
• Jefferson BK, Foster JH, McCarthy JJ, et al. Aspirin resistance and a single gene. Am J Cardiol. 2005;95(6):805–808. doi: 10.1016/j.amjcard.2004.11.045.
   PubMed Web of Science ®Google Scholar
• Laitinen T, Polvi A, Rydman P, et al. Characterization of a common susceptibility locus for asthma-related traits. Science. 2004;304(5668):300–304. doi: 10.1126/science.1090010.
   PubMed Web of Science ®Google Scholar
• Kormann MSD, Carr D, Klopp N, et al. G-protein-coupled receptor polymorphisms are associated with asthma in a large german population. Am J Respir Crit Care Med. 2005;171(12):1358–1362. doi: 10.1164/rccm.200410-1312OC.
   PubMed Web of Science ®Google Scholar
• Melen E, Bruce S, Doekes G, et al. Haplotypes of G protein-coupled receptor 154 are associated with childhood allergy and asthma. Am J Respir Crit Care Med. 2005;171(10):1089–1095. doi: 10.1164/rccm.200410-1317OC.
   PubMed Web of Science ®Google Scholar
• Pietras CO, Vendelin J, Anedda F, et al. The asthma candidate gene NPSR1 mediates isoform specific downstream signalling. BMC Pulm Med. 2011;11(1):39. doi: 10.1186/1471-2466-11-39.
   PubMedGoogle Scholar
• Schöneberg T, Liebscher I. Mutations in G protein–coupled receptors: mechanisms, pathophysiology and potential therapeutic approaches. Pharmacol Rev. 2021;73(1):89–119. doi: 10.1124/pharmrev.120.000011.
   PubMed Web of Science ®Google Scholar
• Dershem R, Metpally RPR, Jeffreys K, et al. Rare-variant pathogenicity triage and inclusion of synonymous variants improves analysis of disease associations of orphan G protein-coupled receptors. J Biol Chem. 2019;294(48):18109–18121. doi: 10.1074/jbc.RA119.009253.
   PubMed Web of Science ®Google Scholar
• Akbari P, Gilani A, Sosina O, et al. Sequencing of 640,000 exomes identifies GPR75 variants associated with protection from obesity. Science. 2021;373(6550):eabf8683. doi: 10.1126/science.abf8683.
   PubMed Web of Science ®Google Scholar
• Thompson MD, Hendy GN, Percy ME, et al. G protein-coupled receptor mutations and human genetic disease. Methods Mol Biol. 2014;1175:153–187.
   PubMedGoogle Scholar
• Giddens MM, Wong JC, Schroeder JP, et al. GPR37L1 modulates seizure susceptibility: evidence from mouse studies and analyses of a human GPR37L1 variant. Neurobiol Dis. 2017;106:181–190. doi: 10.1016/j.nbd.2017.07.006.
   PubMed Web of Science ®Google Scholar
• Socin H, Rubio Almanza M, Tomé Fernández-Ladreda M. Reproduction, smell, and neurodevelopmental disorders: genetic defects in different hypogonadotropic hypogonadal syndromes. Front Endocrinol (Lausanne). 2014;5:109. doi: 10.3389/fendo.2014.00109.
   PubMed Web of Science ®Google Scholar
• Weston MD, Luijendijk MW, Humphrey KD, et al. Mutations in the VLGR1 gene implicate G-protein signaling in the pathogenesis of Usher syndrome type II. Am J Hum Genet. 2004;74:357–366. doi: 10.1086/381685.
   Google Scholar
• Zhou P, Meng H, Liang X, et al. ADGRV1 variants in febrile seizures/epilepsy with antecedent febrile seizures and their associations with audio-visual abnormalities. Front Mol Neurosci. 2022,15:864074. doi: 10.3389/fnmol.2022.864074.
   Google Scholar
• Wang Y, Huso D, Cahill H, et al. Progressive cerebellar, auditory, and esophageal dysfunction caused by targeted disruption of the frizzled-4 gene. J Neurosci. 2001;21:4761–4771.
   Google Scholar
• Xu Q, Wang Y, Dabdoub A, et al. Vascular development in the retina and inner ear: control by norrin and frizzled-4, a high-affinity ligand-receptor pair. Cell. 2004;116:883–895.
   Google Scholar
• Drenser KA, Dailey W, Vinekar A, et al. Clinical presentation and genetic correlation of patients with mutations affecting the FZD4 gene. Arch Ophthalmol. 2009;127(12):1649–1654. doi: 10.1001/archophthalmol.2009.322.
   Google Scholar
• van der Ende SR, Meyers BS, Capasso JE, et al. Severe familial exudative vitreoretinopathy, congenital hearing loss, and developmental delay in a child with biallelic variants in FZD4. JAMA Ophthalmol. 2022;140(9):889–893. doi: 10.1001/jamaophthalmol.2022.2914.
   Google Scholar
• Huang Y, Paxton WA, Wolinsky SM, et al. The role of a mutant CCR5 allele in HIV-1 transmission and disease progression. Nat Med. 1996;2(11):1240–1243. doi: 10.1038/nm1196-1240.
   Google Scholar
• Mohamed H, Gurrola T, Berman R, et al. Targeting CCR5 as a component of an HIV-1 therapeutic strategy. Wigdahl B Front Immunol. 2022;12:816515. doi: 10.3389/fimmu.2021.816515.
   Google Scholar